Breast Cancer Therapy — The Price of Success

New England Journal of Medicine

Volumn 326, Issue 26, 1992, Pages 1774-1775

  Henderson, I Craig ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RISK; CELL CYCLE S PHASE; EDITORIAL; FEMALE; HUMAN; LEUKEMIA; LYMPH NODE METASTASIS; MAMMOGRAPHY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT PLANNING; TUMOR VOLUME;

EID: 0026654888     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199206253262611     Document Type: Editorial

References (8)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1–15, 71–85.
2. Henderson IC. Adjuvant systemic therapy of breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne D, eds. Breast diseases. Philadelphia: J.B. Lippincott, 1991:427–86.
3. Curtis RE, Boice JD Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326: 1745–51.
4. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992; 326: 1756–61.
5. Henderson IC. Prognostic factors. In: Harris JR, Hellman S, Henderson IC, Kinne D, eds. Breast diseases. Philadelphia: J.B. Lippincott, 1991:332–46.
6. Gasparini G, Bevilacqua P, Dal Fior S, et al. Characterization of node-negative breast cancer by clinico-pathologic and biologic factors. Anticancer Res 1990; 10: 205–8.
7. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990; 322: 297–302.
8. Thorpe SM, Rochefort H, Garcia M, et al. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989; 49: 6008–14.